Our Company

Aspiring to be the global leader in p53-targeted cancer therapies

Our Focus

Aprea Therapeutics Inc., (NASDAQ: APRE) is a biopharmaceutical company headquartered in Boston, Massachusetts with research facilities in Stockholm, Sweden, focused on developing and commercializing novel cancer therapeutics to reactivate the mutant tumor suppressor protein p53, the most commonly mutated gene in cancer.

Our Beginnings

Aprea was founded by Klas Wiman, Galina Selivanova, Vladimir Bykov, Staffan Strömblad, Wenjie Bao, Natalia Issaeva and Karolinska Innovations AB at the Karolinska Institute, based on the discovery of PRIMA-1 (p53 reactivation and induction of massive apoptosis). Subsequent enhancement of PRIMA-1 led to APR-246, also known as eprenetapopt, our lead product candidate.

Our Leadership

We have assembled an outstanding team, which includes world class scientific and clinical oncology leaders, to execute on our mission to create novel p53 reactivating therapies to help patients suffering with cancer. Together with our board of directors, our scientific founders and members of our management team have significant experience in drug discovery and development and finance. Collectively, we believe our team’s strong capabilities position us to build a leading biotech company focused on developing novel cancer therapies to address the significant unmet medical need of patients with p53 mutant malignancies, for whom there are limited effective therapeutic options.

Management Team

Christian S. Schade

Chairman and Chief Executive Officer

Christian S. Schade has served as our President and Chief Executive and as a member of our board of directors since June 2016, and was appointed Chairman of the board of directors in September 2020. Mr. Schade has more than 30 years of public and private pharmaceutical and biotechnology industry experience, as well as broad corporate finance expertise from his tenure in investment banking. Prior to joining Aprea, Mr. Schade was Chief Executive Officer of Novira Therapeutics Inc., a privately held antiviral drug discovery company until it was acquired by Johnson & Johnson. He also served as Executive Vice President and Chief Financial Officer of Omthera Pharmaceuticals, Inc., an emerging specialty pharmaceuticals company until it was purchased by AstraZeneca Plc. He previously held executive level positions at NRG Energy, serving as Executive Vice President and Chief Financial Officer, and as Senior Vice President Administration and Chief Financial Officer at Medarex Inc., until it was acquired by Bristol-Myers Squibb Co. He also held various corporate finance and capital markets positions in New York and London for both Merrill Lynch and JP Morgan Chase & Co. Mr. Schade currently serves on the Board of Directors of Integra Life Sciences (NASDAQ: IART) where he chairs the Finance Committee, and on the Board of Directors of Sapience Therapeutics, a privately held company. He received an A.B. degree from Princeton University, and an M.B.A. from the Wharton School at the University of Pennsylvania.

Scott M. Coiante

Senior Vice President and Chief Financial Officer

Scott M. Coiante has served as our Senior Vice President, Chief Financial Officer since August 2019. Mr. Coiante joined Aprea from Agile Therapeutics, or Agile, where he was Senior Vice President and Chief Financial Officer. Having served at Agile since 2010, he played a leadership role in the company and in the development of the internal finance and accounting infrastructure. Prior to joining Agile, he was from 2002 Vice President of Finance and Treasurer at Medarex, Inc., formerly a NASDAQ listed biotech company that was acquired in 2009 by Bristol Myers Squibb. From 1989 to 2002, Mr. Coiante held management positions of increasing responsibilities at Ernst & Young LLP. Mr. Coiante received a B.S. in Accounting from Villanova University.

Eyal C. Attar, M.D.

Senior Vice President and Chief Medical Officer

Eyal C. Attar, M.D. has served as our Senior Vice President, Chief Medical Officer since April 2019. Dr. Attar joined Aprea from Agios Pharmaceuticals, where he was Senior Medical Director and IDH Hematology Medical Lead. Having served at Agios since 2014, Dr. Attar played a leadership role in the clinical development and approval of IDHIFA and TIBSOVO for patients with relapsed/refractory AML. Prior to Agios, he served on the clinical staff at the Massachusetts General Hospital Cancer Center, where Dr. Attar was a member of the Center for Leukemia and Assistant Professor of Medicine at Harvard Medical School. He completed his residency in Internal Medicine at Brigham and Women’s Hospital and held fellowships in hematology and oncology in the Dana-Farber Partners Cancer Care Hematology/Oncology Fellowship Program. Dr. Attar received his medical degree from the University of North Carolina School of Medicine.

Lars Abrahmsen, Ph.D.

Senior Vice President and Chief Scientific Officer

Lars Abrahmsen, Ph.D. has served as our Senior Vice President, Chief Scientific Officer since October 2014. Dr. Abrahmsen has more than 30 years of experience in research and drug development in the pharmaceutical industry, both with small molecules and biopharmaceuticals. Beginning with postdoctoral work at Genentech, he has also worked at Biovitrum, Pharmacia&Upjohn, Pharmacia and KabiGen. More recently he served as Chief Scientific Officer at Affibody from 2004-2010 and as SVP of Protein Therapeutics at Algeta from 2010-2013. Dr. Abrahmsen has experience from discovery research to preclinical development and has primarily focused on projects within oncology and metabolic diseases. Dr. Abrahmsen received a Ph.D. in Biochemistry and an M.S. in Chemistry, both from the Royal Institute of Technology in Stockholm, Sweden.

Gregory S. Wessels

Senior Vice President and Chief Commercial Officer

Gregory S. Wessels has served as our Senior Vice President, Chief Commercial Officer since September 2020, having previously served as VP, Commercial since February 2020. Mr. Wessels has more than 20 years of experience in sales, marketing and commercialization strategy in the pharmaceutical industry. Mr. Wessels joined Aprea from Bristol-Myers Squibb, where he was Executive Director – U.S. Marketing for Lymphoma and Acute Myeloid Leukemia. Mr. Wessels held global and regional oncology marketing positions of increasing responsibility over more than 11 years at Celgene Corporation. Prior to joining Celgene he spent 11 years with Sanofi US in sales, marketing and business planning roles.  Mr. Wessels received a BS in Biochemistry from the University of Notre Dame and an MBA from the Kellogg School of Management at Northwestern University.

Gregory A. Korbel, Ph.D.

Vice President of Business Development

Gregory A. Korbel., Ph.D. has served as our Vice President of Business Development since July 2016. Dr. Korbel has 12 years of experience in the biotechnology and pharmaceutical industries. Prior to joining Aprea Therapeutics, he was Director of Business Development and Operations at Novira Therapeutics, which was acquired in December 2015 by Johnson & Johnson, and served as Director of Research Operations subsequent to the acquisition. In addition to consulting for venture capital and biotechnology firms, he formerly served as Senior Scientist at Invtirogen/Life Technologies. Dr. Korbel received an M.B.A. from the Wharton School at the University of Pennsylvania, a Ph.D. in Chemistry from Harvard University and a B.A. from Vanderbilt University.

Board of Directors

Christian S. Schade

Chairman and Chief Executive Officer

Christian S. Schade has served as our President and Chief Executive and as a member of our board of directors since June 2016, and was appointed Chairman of the board of directors in September 2020. Mr. Schade has more than 30 years of public and private pharmaceutical and biotechnology industry experience, as well as broad corporate finance expertise from his tenure in investment banking. Prior to joining Aprea, Mr. Schade was Chief Executive Officer of Novira Therapeutics Inc., a privately held antiviral drug discovery company until it was acquired by Johnson & Johnson. He also served as Executive Vice President and Chief Financial Officer of Omthera Pharmaceuticals, Inc., an emerging specialty pharmaceuticals company until it was purchased by AstraZeneca Plc. He previously held executive level positions at NRG Energy, serving as Executive Vice President and Chief Financial Officer, and as Senior Vice President Administration and Chief Financial Officer at Medarex Inc., until it was acquired by Bristol-Myers Squibb Co. He also held various corporate finance and capital markets positions in New York and London for both Merrill Lynch and JP Morgan Chase & Co. Mr. Schade currently serves on the Board of Directors of Integra Life Sciences (NASDAQ: IART) where he chairs the Finance Committee, and on the Board of Directors of Sapience Therapeutics, a privately held company. He received an A.B. degree from Princeton University, and an M.B.A. from the Wharton School at the University of Pennsylvania.

Johan Christenson, M.D., Ph.D.

Director

Johan Christenson, M.D., Ph.D. has served as a member of our board of directors since 2016. Dr. Christenson is a Partner of HealthCap. Prior to joining HealthCap in 2001, Dr. Christenson was with SEB Företagsinvest (the venture capital arm of SEB) to supervise its health care portfolio. He has senior management experience from Astra Pain Control as Project Director and AstraZeneca as Global Product Director and member of the global therapy area management team of pain and inflammation. Dr Christenson serves on the boards of Targovax , InCarda and Fusion Pharmaceuticals. He previously served on the boards of Algeta (aquired by Bayer), Oncopeptides and CoreValve (aquired by Medtronic). Dr. Christenson received his medical training at the Karolinska Institute and received his Ph.D. in basic neuroscience in 1991. He served as a lecturer in neuroscience and also held a position as Assistant Dean at the Karolinska Institute Graduate School for two years. Dr. Christenson has four years of clinical specialist training in paediatrics and paediatric neurology.

John B. Henneman

Lead Independent Director

John B. Henneman III has served as a member of our board of directors since August 2019 and was appointed Lead Independent Director in September 2020. Mr. Henneman has more than 25 years of combined financial and operational management experience in the life sciences industry. From July 2018 until November 2018, Mr. Henneman served as the Chief Administrative Officer of NewLink Genetics Corporation, a biotechnology company, and prior to that, served as NewLink’s Executive Vice President and Chief Financial Officer from October 2014 to July 2018. From 1998 to 2014, Mr. Henneman served at Integra LifeSciences Holdings Corp., a publicly-held medical device company, in various capacities. Before becoming Integra’s Chief Financial Officer in 2007, Mr. Henneman was Chief Administrative Officer, responsible for Integra’s regulatory affairs, quality systems, clinical affairs, human resources, information systems and legal affairs functions, the management of Integra’s surgical instruments business, and Integra’s business development function. Mr. Henneman serves on the boards of directors of R1 RCM, Inc., a publicly-held revenue cycle technology and management services company, SeaSpine Holdings Corporation, a publicly-held medical technology company, and Alafair Biosciences, Inc., a privately-held medical device company. Mr. Henneman is also senior advisor to Prettybrook Partners, a private equity firm, and a consultant to SparkMed Advisors LLC, which provides consulting and other services to start-up medical device and biotechnology companies.

Michael A. Kelly

Director

Mr. Kelly joined the Aprea Therapeutics board in September 2020. Mr. Kelly is a former senior executive of Amgen, Inc. and is currently acting as Founder & President of Sentry Hill Partners, LLC, a global life sciences transformation and management consulting business founded by Mr. Kelly in 2018. Mr. Kelly has more than two decades of executive experience as a senior leader in the life sciences industry serving in various strategic finance and operations positions at Amgen Inc., most recently as Senior Vice President, Global Business Services and Vice President & CFO, International Commercial Operations. Mr. Kelly has also held positions at Biogen, Tanox and Monsanto Life Sciences. Mr. Kelly is an independent member of the board of directors for publicly-traded DMC Global, Inc., NeoGenomics, Inc., and Hookipa Pharma, Inc. He also serves on the Council of Advisors and was the former audit committee chairman for Direct Relief, a humanitarian aid organization focused on health outcomes and disaster relief. Mr. Kelly holds a BSc in business administration from Florida A&M University, concentrating in Finance and Industrial Relations.

Fouad Namouni, M.D.

Director

Fouad Namouni, M.D. has served as a member of our board of directors since June 2020. Dr. Namouni brings more than 20 years of oncology and immuno-oncology drug development expertise. He currently serves as President, Research & Development at Blueprint Medicines Corporation. Dr. Namouni joined Blueprint Medicines from Bristol-Myers Squibb (BMS), most recently serving as Senior Vice President & Head of Oncology Development, with responsibility for driving product development plans from early-stage clinical development through commercialization. Prior to serving as Head of Oncology Development, Dr. Namouni was Head of Medical Affairs at BMS and prior to that position, he was Head of Development for Opdivo® and Yervoy®, immunotherapy medications used in the treatment of cancer. Dr. Namouni holds an M.D. degree from the University of Annaba Medical School in Algeria, and a Pediatrics degree from Université Rene Descartes in Paris, France. In addition, he received a Pediatric Oncology and Hematology degree and M.S. in clinical and experimental pharmacology from Université Paris-Sud in France.

Richard Peters, M.D., Ph.D.

Director

Richard Peters, M.D., Ph.D. has served as a member of our board of directors since June 2020. Dr. Peters brings more than 25 years of experience developing new therapies for difficult-to-treat diseases. He currently serves as President, Chief Executive Officer and Director at Yumanity Therapeutics Inc. Dr. Peters joined Yumanity from Merrimack Pharmaceuticals, Inc. where he was President & Chief Executive Officer. Prior to Merrimack, he served as Senior Vice President and Head, Global Rare Diseases at Genzyme (Sanofi). Dr. Peters is a Harvard-trained physician and scientist, has served on the faculty at the Massachusetts General Hospital, and completed a Howard Hughes Medical Institute Fellowship in biophysics at Harvard Medical School. Dr. Peters commenced his medical studies at UC Louvain in Belgium and holds M.D. and Ph.D. degrees from the Medical University of South Carolina.

Bernd R. Seizinger, M.D., Ph.D.

Director

Bernd Seizinger, M.D., Ph.D., has served as a member of our board of directors since 2016. Dr. Seizinger currently serves as chairman/board member in a number of public and private biotech companies in the U.S., Europe and Canada, including: Oxford BioTherapeutics, Aprea, CryptoMedix, Oncolytics and BioInvent. Previously he was President & CEO of GPC Biotech; VP Oncology Drug Discovery and – in parallel – VP Corporate and Academic Alliances at Bristol-Myers Squibb; Executive VP and CSO, Genome Therapeutics; Senior Faculty positions at Harvard Medical School, Massachusetts General Hospital and Princeton University.